Anti-tumor activity of lipophilic imidazolium salts on select NSCLC cell lines

被引：30

作者：

Wright, Brian D. ^{[1
]}

Deblock, Michael C. ^{[1
]}

Wagers, Patrick O. ^{[1
]}

Duah, Ernest ^{[1
]}

Robishaw, Nikki K. ^{[1
]}

Shelton, Kerri L. ^{[1
]}

Southerland, Marie R. ^{[1
]}

DeBord, Michael A. ^{[1
]}

Kersten, Kortney M. ^{[1
]}

McDonald, Lucas J. ^{[1
]}

Stiel, Jason A. ^{[1
]}

Panzner, Matthew J. ^{[1
]}

Tessier, Claire A. ^{[1
]}

Paruchuri, Sailaja ^{[1
]}

Youngs, Wiley J. ^{[1
]}

机构：

[1] Univ Akron, Dept Chem, Akron, OH 44325 USA

来源：

MEDICINAL CHEMISTRY RESEARCH | 2015年 / 24卷 / 07期

基金：

美国国家科学基金会; 美国国家卫生研究院;

关键词：

Imidazolium cation; Imidazolium salt; Anti-tumor; Anticancer; Apoptosis; SILVER CARBENE COMPLEXES; STRUCTURAL CHARACTERIZATION; CISPLATIN;

D O I：

10.1007/s00044-015-1330-z

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The anti-tumor activity of imidazolium salts is highly dependent upon the substituents on the nitrogen atoms of the imidazolium cation. We have synthesized and characterized a series of naphthalene-substituted imidazolium salts and tested them against a variety of non-small-cell lung cancer cell lines. Several of these complexes displayed anticancer activity comparable to cisplatin. These compounds induced apoptosis in the NCI-H460 cell line as determined by Annexin V staining, caspase-3, and PARP cleavage. These results strongly suggest that this class of compounds can serve as potent chemotherapeutic agents.

引用

页码：2838 / 2861

页数：24

共 50 条

[31] Histone Deacetylase Inhibitor Romidepsin Enhances Anti-Tumor Effect of Erlotinib in Non-small Cell Lung Cancer (NSCLC) Cell Lines
Zhang, Wei
Peyton, Michael
Xie, Yang
Soh, Junichi
Minna, John D.
Gazdar, Adi F.
Frenkel, Eugene P.
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (02) : 161 - 166
[32] IMMUNOLOGICAL STUDIES ON ANTI-TUMOR ACTIVITY OF YEAST-CELL WALL .1. ANTI-TUMOR ACTIVITY AND ITS EFFECTS BY IMMUNOSUPPRESSION
SHIMIZU, T
HARAGUCHI, S
MIFUCHI, I
NAKANO, M
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 1978, 98 (08): : 1028 - 1034
[33] DOES COLOR OF AN ANTI-TUMOR AGENT PREDICT FOR CLINICAL ANTI-TUMOR ACTIVITY
VONHOFF, DD
KUHN, J
CLARK, G
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1981, 6 (01) : 93 - 94
[34] ANTI-TUMOR ACTIVITY AND CELL KINETIC EFFECTS OF PYRAZOFURIN INVITRO
HILL, BT
WHELAN, RDH
EUROPEAN JOURNAL OF CANCER, 1980, 16 (12) : 1633 - 1638
[35] Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity
Miret, Juan J.
Kirschmeier, Paul
Koyama, Shohei
Zhu, Mingrui
Li, Yvonne Y.
Naito, Yujiro
Wu, Min
Malladi, Venkat S.
Huang, Wei
Walker, William
Palakurthi, Sangeetha
Dranoff, Glenn
Hammerman, Peter S.
Pecot, Chad V.
Wong, Kwok-Kin
Akbay, Esra A.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[36] GILVOCARCINS, NEW ANTI-TUMOR ANTIBIOTICS .3. ANTI-TUMOR ACTIVITY
MORIMOTO, M
OKUBO, S
TOMITA, F
MARUMO, H
JOURNAL OF ANTIBIOTICS, 1981, 34 (06): : 701 - 707
[37] Anti-tumor effects of a selective MET inhibitor on clear cell sarcoma cell lines
Nakai, Takaaki
Imura, Yoshinori
Nakai, Sho
Yasuda, Naohiro
Yamada, Shutaro
Takenaka, Satoshi
Tamiya, Hironari
Tanaka, Takaaki
Araki, Nobuhito
Itoh, Kazuyuki
Yoshikawa, Hideki
Naka, Norifumi
CANCER SCIENCE, 2018, 109 : 569 - 569
[38] IL-6 contributes to the suppression of T and NK cell anti-tumor activity in EGFR-mutant NSCLC
Patel, Sonia
Nilsson, Monique
Yang, Yan
Yu, Xiaoxing
Zhang, Fahao
Poteete, Alissa
Ren, Xiaoyang
Shen, Li
Wang, Jing
Le, Xiuning
Heymach, John
CANCER RESEARCH, 2022, 82 (12)
[39] Anti-tumor activity of ADH-1 in vitro and in vivo in combination with paclitaxel in ovarian cancer cell lines
Gupta, M.
Barnes, D.
Losos, J.
Spehar, G.
Bednarcik, M.
Peters, W. P.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[40] Anti-tumor activity of the HSP90 inhibitor SNX-2112 in pediatric cancer cell lines
Chinn, Danielle C.
Holland, William S.
Yoon, Janet M.
Zwerdling, Theodore
Mack, Philip C.
PEDIATRIC BLOOD & CANCER, 2012, 58 (06) : 885 - 890

← 1 2 3 4 5 →